The ScanNanoTreat Consortium
A European Alliance Driving the Future of Theranostics
ScanNanoTreat brings together a powerful consortium of leading universities, industry innovators, and commercialisation specialists from across Europe. Each partner contributes unique expertise in medical imaging, nanotechnology, photonics, oncology, regulatory science, and market exploitation.
Together, this multidisciplinary team is transforming a scientific breakthrough into a scalable, clinically ready, commercially viable theranostic platform for solid tumour treatment.
UNIVERSITÉ CLAUDE BERNARD LYON 1 (UCBL) Project Coordinator, France
UCBL leads the ScanNanoTreat project, coordinating the scientific and technical development of the integrated imaging and therapeutic platform. As one of France’s top research universities in biomedical science, UCBL provides world-class expertise in oncology, nanotechnology, and translational research. The Chemistry Laboratory as well as CREATIS laboratory contribute deeply to nanoprobe development, preclinical studies, and integration of photonics-based therapy approaches.
Lyon Ingénierie Projets (LIP)
Affiliate Entity, France
LIP, the engineering subsidiary of Université Claude Bernard Lyon 1 and UCBL’s affiliated entity in the ScanNanoTreat project, ensures the effective implementation of the project by overseeing compliance with the grant agreement, monitoring timelines, and enforcing funding rules. LIP also manages financial and administrative aspects, facilitates smooth collaboration among partners, and contributes to the successful delivery of the project’s objectives.
Universiteit Maastricht (UM)
Beneficiary, Netherlands
Maastricht University is a key research partner, contributing advanced knowledge in photodynamic therapy, biomedical imaging, and nanomedicine. UM supports the optimisation of nanoprobe activation mechanisms and preclinical evaluation of the combined imaging-therapy workflow. Its interdisciplinary teams help ensure the system reaches the required performance, safety, and translational milestones.
Guerbet SA
Industrial Beneficiary, France
Guerbet is a global leader in contrast agents and interventional radiology solutions. In ScanNanoTreat, Guerbet provides industrial expertise in nanoprobe formulation, safety optimisation, regulatory compliance, and future industrial scale-up. Their participation ensures that the project’s nanotechnology innovations are aligned with real-world clinical requirements and medical market standards.
Philips France
Industrial Beneficiary, France
Philips is a world-leading developer of medical imaging systems, including next-generation CT scanners. Within ScanNanoTreat, Philips contributes system-level integration, imaging workflow design, and performance optimisation of Spectral Photon Counting CT. Their role is critical in ensuring the new theranostic system fits safely and effectively into real clinical imaging environments.
Inlecom Commercial Pathways (ICP) Commercialisation & Exploitation Beneficiary, Ireland
ICP leads the business planning, exploitation strategy, IP management support, and future spin-off preparation for ScanNanoTreat. Their role includes: Market analysis ; Commercial model development ; Regulatory pathway planning ; Investor-readiness and go-to-market strategy. ICP ensures the technology not only demonstrates scientific excellence but achieves long-term impact through strong commercial deployment.
